Extract from Bell Potter research report of 01/09/23:
The trial is expected to cost MSB in the range of US$6-$9m (mid single digits). BM-CTN
will conduct the adult trial and meet some of the funding requirement.
First patient enrolment is likely in 1QCY24.
Ann: Half Year Report and Accounts (including Appendix 4D), page-18
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
-0.048(3.15%) |
Mkt cap ! $1.681B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $6.546M | 4.464M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 10610 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 65734 | 20 |
View Market Depth
| Last trade - 14.48pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |